NovaBay Pharmaceuticals, Inc. (NBY) Stock

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris. The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments. The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007. Its corporate headquarters are located in Emeryville, California.

NovaBay Pharmaceuticals, Inc. is headquartered in US.

NovaBay Pharmaceuticals, Inc. (NBY) stock trades at $1.47 with a market capitalization of $39.14M. The stock is valued at a price-to-earnings (P/E) ratio of 0.09, price-to-book of 0.28, price-to-sales of 15.89. Over the past 52 weeks the stock has ranged between $1.11 and $99.75, and currently trades 98.5% below its 52-week high. It pays a dividend yielding 2.72%.

On profitability, NovaBay Pharmaceuticals, Inc. generates a return on equity (ROE) of 95.65% — well above the market average, a sign of a high-quality business, return on capital employed of -2.66%, an operating margin of -190.01%.

Official website: novabay.com